Overview

Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

Pegylation of interferon prolongs the medication half-life which has resulted in Pegylated Interferon (PEG-IFN) as the new modality for treatment of chronic hepatitis C. We current this clinical trial to assess the efficacy and safety of domestic PEG-IFN alpha-2a (Pegaferon®) in the patients with chronic hepatitis C.

Phase:

Phase 3

Details

Lead Sponsor:

Tehran Hepatitis Center

Collaborator:

Kermanshah University of Medical Sciences

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin